Page last updated: 2024-08-24

fadrozole and aromasil

fadrozole has been researched along with aromasil in 10 studies

Research

Studies (10)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (60.00)	29.6817
2010's	2 (20.00)	24.3611
2020's	2 (20.00)	2.80

Authors

Authors	Studies
Chen, JZ; Khan, MZI; Nazli, A; Uzair, M	1
Sonoo, H	1
Auvray, P; Bichat, F; Genne, P	1
de Crémoux, P	1
Buzdar, A; Howell, A	1
Buzdar, AU	1
Dutta, U; Pant, K	1
Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nagase, H; Noguchi, S	1
Hartmann, RW; Hu, Q; Yin, L	1
Amaral, C; Fernandes, PA; Ferreira Almeida, C; João Ramos, M; Oliveira, A; Teixeira, N	1

Reviews

8 review(s) available for fadrozole and aromasil

Article	Year
An overview on Estrogen receptors signaling and its ligands in breast cancer. European journal of medicinal chemistry, 2022, Nov-05, Volume: 241 Topics: Breast Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Humans; Ligands; Male; Receptors, Estrogen	2022
[Aromatase inhibitors for treatment of advanced breast cancers]. Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58 Suppl Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Fadrozole; Female; Humans; Letrozole; Nitriles; Treatment Outcome; Triazoles	2000
[Preclinical evaluation of aromatase inhibitors antitumor activity]. Bulletin du cancer, 2000, Volume: 87 Spec No Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fadrozole; Female; Humans; Letrozole; Models, Animal; Nitriles; Rats; Structure-Activity Relationship; Triazoles	2000
[Aromatase inhibitors: pharmacological aspects]. Bulletin du cancer, 2000, Volume: 87 Spec No Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Enzyme Inhibitors; Fadrozole; Female; Humans; Letrozole; Nitriles; Triazoles	2000
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:9 Topics: Anastrozole; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Fadrozole; Female; Headache; Humans; Letrozole; Nausea; Nitriles; Treatment Outcome; Triazoles; Vomiting	2001
A summary of second-line randomized studies of aromatase inhibitors. The Journal of steroid biochemistry and molecular biology, 2001, Volume: 79, Issue:1-5 Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Tolerance; Enzyme Inhibitors; Estrogen Receptor Modulators; Fadrozole; Female; Humans; Letrozole; Megestrol Acetate; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles	2001
Aromatase inhibitors: past, present and future in breast cancer therapy. Medical oncology (Northwood, London, England), 2008, Volume: 25, Issue:2 Topics: Aminoglutethimide; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Fadrozole; Female; Humans; Letrozole; Nitriles; Triazoles	2008
Estrogen receptor-positive (ER Biochemical pharmacology, 2020, Volume: 177 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Fadrozole; Female; Fulvestrant; Gene Expression; Humans; Molecular Targeted Therapy; Tamoxifen	2020

Other Studies

2 other study(ies) available for fadrozole and aromasil

Article	Year
Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors. Oncology, 2010, Volume: 79, Issue:1-2 Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estrogen Receptor alpha; Estrogen Receptor beta; Fadrozole; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Nitriles; Phosphorylation; Predictive Value of Tests; Prognosis; Retrospective Studies; Serine; Tamoxifen; Triazoles	2010
3-Pyridyl substituted aliphatic cycles as CYP11B2 inhibitors: aromaticity abolishment of the core significantly increased selectivity over CYP1A2. PloS one, 2012, Volume: 7, Issue:11 Topics: Algorithms; Androstadienes; Aromatase Inhibitors; Catalytic Domain; Cytochrome P-450 CYP11B2; Cytochrome P-450 CYP1A2 Inhibitors; Drug Design; Enalapril; Eplerenone; Fadrozole; Humans; Inhibitory Concentration 50; Models, Chemical; Models, Molecular; Molecular Conformation; Spironolactone; Structure-Activity Relationship; Temperature	2012

Article

Year

Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.

Oncology, 2010, Volume: 79, Issue:1-2

Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estrogen Receptor alpha; Estrogen Receptor beta; Fadrozole; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Nitriles; Phosphorylation; Predictive Value of Tests; Prognosis; Retrospective Studies; Serine; Tamoxifen; Triazoles

2010

3-Pyridyl substituted aliphatic cycles as CYP11B2 inhibitors: aromaticity abolishment of the core significantly increased selectivity over CYP1A2.

PloS one, 2012, Volume: 7, Issue:11

Topics: Algorithms; Androstadienes; Aromatase Inhibitors; Catalytic Domain; Cytochrome P-450 CYP11B2; Cytochrome P-450 CYP1A2 Inhibitors; Drug Design; Enalapril; Eplerenone; Fadrozole; Humans; Inhibitory Concentration 50; Models, Chemical; Models, Molecular; Molecular Conformation; Spironolactone; Structure-Activity Relationship; Temperature

2012